Magnetic Resonance Imaging Outcomes in Colchicine After Stroke to Prevent Event Recurrence (CASPER) study cohort: An Imaging sub-study of Colchicine After Stroke to Prevent Event Recurrence.

The cohort of participants randomized into the intervention arm of CASPER [ACTRN12621001408875] i.e., taking oral Colchicine 0.5mg tablet daily for median 3 years will make up the intervention arm of participants in the MR-CASPER sub-study, and will upon completing registration, run-in and randomization phases of CASPER [ACTRN12621001408875] undergo: - Baseline Magnetic Resonance Imaging (MRI), with no contrast dye injected and a projected 30 min total scan time will be conducted by radiologist. -Baseline cognitive assessment; Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT) and Brief Memory and Executive Test (BMET) performed by study investigators. -Baseline mood assessment; Depression, Anxiety and Stress Scale 42 (DASS 42) performed by study investigators. -Baseline Quality of life assessment; 36-item short form survey (SF-36) performed by study investigators. - Follow-up MRI annually with no contrast dye injected and a projected 30 min total scan time, in line with the 12month, 24 month and 36month follow-up visits employed in the parent study CASPER [ACTRN12621001408875] conducted by radiologist. - Follow-up cognitive (MOCA, TMT, BMET), mood (DASS 42) and quality of life (SF-36) clinical assessments are projected to take up to 45min, in line with the 12month, 24 month and 36month follow-up visits employed in the parent study CASPER [ACTRN12621001408875] conducted by study investigators. Participant adherence to the MRI intervention will be monitored by scheduled visits attendance checklists. Trial synergies include using concurrent assessment time-points for both studies, with assessors also shared to further reduce participant burden.